10-K: Bionano Genomics Reports Full Year 2024 Results, Focuses on OGM Adoption

Bionano Genomics reports a 15% decrease in total revenue for 2024, shifting focus to installed base utilization and cost savings.

Summary

• Bionano Genomics' 10-K filing reveals a strategic shift towards maximizing the utilization of its existing installed base of OGM systems.
• The company reported total revenue of $30.8 million for the year ended December 31, 2024, a 15% decrease compared to $36.1 million in 2023.
• The installed base of OGM systems grew by 14% to 371 as of December 31, 2024.
• The company sold 30,307 flowcells in 2024, a 15% increase year-over-year.
• Bionano Laboratories phased out certain testing services for neurodevelopmental disorders during 2024.
• The company is implementing cost-saving initiatives, including headcount reductions, to extend its cash runway.
• Bionano believes its current cash, cash equivalents, and short-term investments will fund operations into the first quarter of 2026.
• The company acknowledges substantial doubt about its ability to continue as a going concern without additional financing.
• Bionano is exploring strategic alternatives to maximize stakeholder value.
• The company is subject to risks related to geopolitical and macroeconomic developments.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive aspects, such as the growth in the installed base and flowcell sales, the overall tone is cautious due to the revenue decline, ongoing losses, and the going concern warning. The strategic review adds uncertainty.

Positives

• Installed base of OGM systems increased by 14% to 371.
• Flowcell sales increased by 15% to 30,307.
• Software revenue increased by 11% to $6.2 million.
• The company is implementing cost-saving initiatives to extend its cash runway.
• The AMA established a category I CPT code for OGM in heme malignancies (code 81195) which was priced by the Clinical Laboratory Fee Schedule (CLFS) and effective Jan 1, 2025.

Negatives

• Total revenue decreased by 15% to $30.8 million.
• Instrument revenue decreased by 20% to $8.0 million.
• Service and other revenue decreased by 60% to $3.8 million.
• The company has incurred net losses since inception and expects to continue to incur losses.
• There is substantial doubt about Bionano's ability to continue as a going concern without additional financing.
• Bionano Laboratories phased out certain testing services for neurodevelopmental disorders during 2024.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• Cost-saving initiatives may disrupt the business and may not achieve intended objectives.
• The company faces risks associated with unfavorable geopolitical and macroeconomic developments.
• The company's products or technologies may fail to achieve and sustain sufficient market acceptance.
• The company may be unable to protect its intellectual property.
• The company may be unable to maintain its listing on the Nasdaq Capital Market.
• The price of the company's securities may be volatile or may decline regardless of operating performance.
• The company may not be successful in identifying and implementing any potential strategic alternatives.
• If a strategic transaction is not consummated, the Board may decide to pursue a dissolution and liquidation.

Future Outlook

Bionano expects to continue to incur significant expenses and operating losses. The company believes its current cash, cash equivalents, and short-term investments will fund operations into the first quarter of 2026. The company is exploring strategic alternatives to maximize stakeholder value.

Management Comments

• The board of directors has established a strategy committee to work with the Company and outside advisors in evaluating our options and considering alternatives that we believe will maximize stakeholder value, including any of the following or a combination thereof: debt financing, equity investments, combinations with other companies, or the sale of all or part of the company.

Industry Context

The genomics market is expected to grow, but Bionano faces competition and must demonstrate the value of its OGM technology compared to existing methods.

Comparison to Industry Standards

• The document mentions competitors such as Nabsys, PacBio, Oxford Nanopore Technologies, Qiagen, Dovetail Genomics (now part of Cantata Bio), and Arima.
• It states that OGM has been shown to outperform current gold standard cytogenetic methods including karyotyping, fluorescence in-situ hybridization (FISH), Southern blot and chromosomal microarray (CMA), for the detection of SVs.
• It also states that OGM has also been shown to identify structural changes in chromosomes that cannot be identified using current commercially available gene sequencing solutions.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment.
• Employees may be affected by headcount reductions and restructuring.
• Customers may experience changes in product availability and support.
• Suppliers may be impacted by changes in the company's purchasing patterns.
• Creditors face the risk of default if the company is unable to secure additional financing.

Next Steps

• Continue to drive adoption of OGM through the existing installed base.
• Explore strategic alternatives to maximize stakeholder value.
• Implement cost-saving initiatives to extend the cash runway.
• Seek additional financing to fund operations.

Key Dates

Keywords

optical genome mapping, OGM, Bionano Genomics, revenue, installed base, flowcells, cost savings, going concern, strategic alternatives, financial results, genomics, VIA software, Stratys system, Saphyr system, Ionic Purification system